Culture, arts & science

QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

NEWARK, Del.–(BUSINESS WIRE)– QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy...

Asymchem Appoints Dr. Cheng Yi Chen as CTO of Small-Molecule Sector

TEDA TIANJIN, China–(BUSINESS WIRE)– In line with Asymchem’s continuous strategic layout and development, the organization has welcomed Dr. Cheng Yi Chen as a senior executive....

AMGTA Recognizes Sustainability Accomplishments at Annual Member Summit

Group acknowledges member efforts toward more sustainable manufacturing practices LOS ANGELES–(BUSINESS WIRE)– The Additive Manufacturer Green Trade Association (AMGTA), a global advocacy group focused on...

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Not intended for UK-, US- or Canada-based media DARMSTADT, Germany–(BUSINESS WIRE)– Merck, a leading science and technology company, today announced the discontinuation of the Phase...

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common and...

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161 Mezagitamab Had a...

Lifezone Metals maakt stemresultaten bekend van de jaarlijkse algemene vergadering van 2024

DOUGLAS, Het eiland Man–(BUSINESS WIRE)– Lifezone Metals Limited (NYSE: LZM) maakt de stemresultaten bekend van de aandeelhouders op de jaarlijkse algemene vergadering van 2024 (de...

Esri-technologie toegepast door het ALS Therapy Development Institute om klinische onderzoeken in kaart te brengen

Met de ALS Trial Navigator kunnen mensen met ALS eenvoudig zoeken naar onderzoeken waarvoor ze mogelijk in aanmerking komen REDLANDS, Californië–(BUSINESS WIRE)– Het ALS Therapy...

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials

ALS Trial Navigator Offers People Living with ALS an Easy Way to Search Eligible Research Studies REDLANDS, Calif.–(BUSINESS WIRE)– The ALS Therapy Development Institute (ALS...

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting

DOUGLAS, Isle of Man–(BUSINESS WIRE)– Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”)...

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for...

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day...

Biocytogen werd een U.S.-patent toegekend voor het RenLite®-platform voor muizen met gewone lichte ketens

BEIJING–(BUSINESS WIRE)– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) kondigt de toekenning aan van het USPTO-patent (United States Patent & Trademark Office) voor het...

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

BEIJING–(BUSINESS WIRE)– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully...

Melodia Therapeutics en Alivexis ondertekenen een exclusieve licentieovereenkomst voor het Cathepsin C Inhibitor-programma MOD-A

TOKIO–(BUSINESS WIRE)– Alivexis, Inc. (met hoofdzetel in Tokio, Japan, “Alivexis”) en Melodia Therapeutics AG (met hoofdzetel in Basel, Zwitserland, “Melodia”), een bedrijf opgericht door Forty51...